公开(公告)号：US07825245B2

公开(公告)日：2010-11-02

申请号：US11939265

申请日：2007-11-13

Applicant: Wenlin Huang ,  Xiaohong Zhou

Inventor： Wenlin Huang ,  Xiaohong Zhou

IPC: C07D239/72

CPC classification number: C07D239/94

Abstract: The present invention relates to quinazoline derivatives of formula I: wherein X, Y, Z, R1, R2, R3, and R4 are as defined herein. The invention also relates to a method of preparing these compounds, and use of these compounds for inhibiting tumor growth.

Abstract translation: 本发明涉及式I的喹唑啉衍生物：其中X，Y，Z，R 1，R 2，R 3和R 4如本文所定义。 本发明还涉及制备这些化合物的方法，以及这些化合物用于抑制肿瘤生长的用途。

公开(公告)号：US20080167328A1

公开(公告)日：2008-07-10

申请号：US11939265

申请日：2007-11-13

Applicant: Wenlin Huang ,  Xiaohong Zhou

Inventor： Wenlin Huang ,  Xiaohong Zhou

IPC: A61K31/517 ,  C07D239/94 ,  A61P35/00

CPC classification number: C07D239/94

Abstract: The present invention relates to quinazoline derivatives of formula I: wherein X, Y, Z, R1, R2, R3, and R4 are as defined herein. The invention also relates to a method of preparing these compounds, and use of these compounds for inhibiting tumor growth.

Abstract translation: 本发明涉及式I的喹唑啉衍生物：其中X，Y，Z，R 1，R 2，R 3和R 3 4 如本文所定义。 本发明还涉及制备这些化合物的方法，以及这些化合物用于抑制肿瘤生长的用途。

公开(公告)号：US20080267992A1

公开(公告)日：2008-10-30

申请号：US11628518

申请日：2004-06-04

Applicant: Wenlin Huang ,  Yixin Zeng ,  Jian Wang ,  Ranyi Liu ,  Jialing Huang ,  Bijun Huang ,  Kun Lai ,  Lizhi Wu ,  Zhihui Liang ,  Miaola Ke ,  Xiuju Wu

Inventor： Wenlin Huang ,  Yixin Zeng ,  Jian Wang ,  Ranyi Liu ,  Jialing Huang ,  Bijun Huang ,  Kun Lai ,  Lizhi Wu ,  Zhihui Liang ,  Miaola Ke ,  Xiuju Wu

IPC: A61K39/00 ,  C12N15/87 ,  A61P37/00

CPC classification number: A61K39/215 ,  A61K39/12 ,  A61K2039/53 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2770/20034

Abstract: The present invention relates to the field of biological engineering technology, specifically, to a SARS virus vaccine with adenovirus carrier, preparation method thereof and use of SARS virus S gene for preparation of severe acute respiratory syndrome (SARS) virus vaccine.

Abstract translation: 本发明涉及生物工程技术领域，具体涉及具有腺病毒载体的SARS病毒疫苗，其制备方法和使用SARS病毒S基因制备严重急性呼吸综合征（SARS）病毒疫苗。

公开(公告)号：US20080177068A1

公开(公告)日：2008-07-24

申请号：US11939244

申请日：2007-11-13

Applicant: Wenlin Huang ,  Xiaohong Zhou

Inventor： Wenlin Huang ,  Xiaohong Zhou

IPC: C07D239/94

CPC classification number: C07D239/94

Abstract: The present invention relates to quinazoline derivatives represented by general formula (I): wherein X, Y, Z, R1, R2, R3, and R4 are as defined herein. The invention also relates to a method of preparing these compounds, and use of these compounds for inhibiting tumor growth.

Abstract translation: 本发明涉及由通式（I）表示的喹唑啉衍生物：其中X，Y，Z，R 1，R 2，R 3， >和R 4'如本文所定义。 本发明还涉及制备这些化合物的方法，以及这些化合物用于抑制肿瘤生长的用途。

公开(公告)号：US20160090362A1

公开(公告)日：2016-03-31

申请号：US14891237

申请日：2014-05-20

Applicant: Wenlin HUANG ,  Kayode OJO ,  UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： Erkang FAN ,  Wesley C. VAN VOORHIS ,  Zhongsheng ZHANG ,  Wenlin HUANG, ,  Kayode K. OJO

IPC: C07D231/38 ,  C07D401/06 ,  C07D405/14 ,  C07D405/04 ,  C07D401/04 ,  C07D231/14 ,  C07D403/04

CPC classification number: A61K31/4709 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/5377 ,  C07D231/14 ,  C07D231/38 ,  C07D235/08 ,  C07D235/12 ,  C07D311/20 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D487/04 ,  Y02A50/488

Abstract: The present disclosure is generally directed to compositions and methods for treating apicomplexan protozoan related disease, such as toxoplasmosis and cryptosporidiosis.

Abstract translation: 本公开一般涉及用于治疗类似原生动物原生动物相关疾病如弓形虫病和隐孢子虫病的组合物和方法。

公开(公告)号：US20130095558A1

公开(公告)日：2013-04-18

申请号：US13549607

申请日：2012-07-16

Applicant: Wenlin Huang

Inventor： Wenlin Huang

IPC: C12N7/02

CPC classification number: C12N7/02 ,  C12N7/00 ,  C12N2710/10032 ,  C12N2710/10051

Abstract: This invention discloses a production process for recombinant human endostatin adenovirus in order to optimize the procedure for small batch and mass industrialization. Exemplary process include steps of: (1) fermentation of eukaryotic cells (HEK293 cells) in the condition of 37° C. and 5% CO2; (2) adenovirus infection; (3) collection of diseased cells; (4) freezing and thawing; (5) concentration by ultrafiltration; and (6) preparation and packaging of recombinant human endostatin adenovirus. The process is controllable and easy to operate. The concentration of adenovirus titers can reach 1.0×1012−3.0×1012 vp/ml.

Abstract translation: 本发明公开了一种重组人内皮抑素腺病毒的制备方法，以优化小批量和大规模工业化的程序。 示例性方法包括以下步骤：（1）在37℃和5％CO 2条件下发酵真核细胞（HEK293细胞）; （2）腺病毒感染; （3）收集病变细胞; （4）冻融; （5）超滤浓缩; 和（6）重组人内皮抑素腺病毒的制备和包装。 该过程是可控的，易于操作。 腺病毒滴度的浓度可达1.0×1012-3.0×1012vp / ml。

公开(公告)号：US20130216499A1

公开(公告)日：2013-08-22

申请号：US13762185

申请日：2013-02-07

Applicant: Wenlin Huang

Inventor： Wenlin Huang

IPC: A61K9/19 ,  A61K35/76

CPC classification number: A61K9/19 ,  A61K9/0019 ,  A61K35/761 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26

Abstract: The invention generally relates to compositions of and methods for production of recombinant adenoviruses that carry therapeutic genes. More particularly, the invention relates to lyophilized recombinant adenoviruses injection and its related production procedures, including production procedures for the recombinant adenovirus vectors (or other viral vectors) that carry the genes of human endostatins.

Abstract translation: 本发明一般涉及携带治疗基因的重组腺病毒的制备方法和方法。 更具体地，本发明涉及冻干重组腺病毒注射剂及其相关的制备方法，包括携带人内皮抑素基因的重组腺病毒载体（或其它病毒载体）的制备方法。

公开(公告)号：US20130028868A1

公开(公告)日：2013-01-31

申请号：US13549629

申请日：2012-07-16

Applicant: Wenlin Huang

Inventor： Wenlin Huang

IPC: A61K48/00 ,  A61P35/00 ,  A61P9/00 ,  C12N15/63

CPC classification number: C12N7/02 ,  C12N7/00 ,  C12N2710/10032 ,  C12N2710/10051

Abstract: The present invention relates to the genetic engineering field of angiogenesis-targeted therapy. Particularly, a recombinant human endostatin adenovirus injection is used along with certain antitumor agents for treating specific tumors. The methods of the invention offer significant improvement of effective response rate, disease control rate, survival and quality of life. The injection and treatment has no significant adverse reactions and side effects.

Abstract translation: 本发明涉及血管生成靶向治疗的基因工程领域。 特别地，与某些抗肿瘤剂一起使用重组人内皮抑素腺病毒注射用于治疗特定肿瘤。 本发明的方法提供了有效的应答率，疾病控制率，存活和生活质量的显着改善。 注射和治疗没有明显的不良反应和副作用。

公开(公告)号：US20080182985A1

公开(公告)日：2008-07-31

申请号：US11939291

申请日：2007-11-13

Applicant: Wenlin Huang ,  Xiaohong Zhou

Inventor： Wenlin Huang ,  Xiaohong Zhou

IPC: C07D239/94

CPC classification number: C07D239/94

Abstract: The present invention relates to quinazoline derivatives represented by general formula (I): wherein X, Y, Z, R1, R2, R3, and R4 are as defined herein. The invention also relates to a method of preparing these compounds, and use of these compounds for inhibiting tumor growth.

Abstract translation: 本发明涉及由通式（I）表示的喹唑啉衍生物：其中X，Y，Z，R 1，R 2，R 3， >和R 4'如本文所定义。 本发明还涉及制备这些化合物的方法，以及这些化合物用于抑制肿瘤生长的用途。

公开(公告)号：US06440658B1

公开(公告)日：2002-08-27

申请号：US09705618

申请日：2000-11-03

Applicant: Wenlin Huang ,  Shalom Z. Hirschman

Inventor： Wenlin Huang ,  Shalom Z. Hirschman

IPC: C12Q170

CPC classification number: C12Q1/18 ,  G01N33/5008 ,  G01N2510/00

Abstract: An assay method for determining the effect of Product R on virus infection of Hela cells. The method comprising the following step: (1) dividing Hela cells into several groups, (2) treating one group with Product R prior to infecting the cells with a virus and treating another group with Product R after the cells being infected with the virus, and (3) determining the effects of Product R on virus infection by comparing the changes in the cell cycle, DNA fragmentation and p53 protein in cells undergone the different treatments in step (2).

Abstract translation: 用于确定产品R对Hela细胞病毒感染的影响的测定方法。 该方法包括以下步骤：（1）将Hela细胞分成几组，（2）在用病毒感染细胞之前用产物R处理一组，并在细胞被病毒感染后用产品R处理另一组， （3）通过比较步骤（2）中经过不同处理的细胞中细胞周期，DNA断裂和p53蛋白的变化，确定产品R对病毒感染的影响。